Tian Li

Shuguang, 201900, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Concurrent human epidermal growth factor receptor 2-positive breast cancer with axillary nodal metastasis in a patient with pituitary prolactinoma: a case report.

Concurrent human epidermal growth factor receptor 2-positive breast cancer with axillary nodal metastasis in a patient with pituitary prolactinoma: a case report.

Journal: AME case reports

Published: January 20, 2026

Efficacy and Safety of Shen-Ling-Lian-Xia Granule Combined With Neoadjuvant Chemotherapy in Patients With Triple-Negative Breast Cancer: Protocol for a Randomized, Double-Blind, Multicenter Clinical Trial.

Efficacy and Safety of Shen-Ling-Lian-Xia Granule Combined With Neoadjuvant Chemotherapy in Patients With Triple-Negative Breast Cancer: Protocol for a Randomized, Double-Blind, Multicenter Clinical Trial.

Journal: JMIR research protocols

Published: January 15, 2026

Formononetin triggers ferroptosis in triple-negative breast cancer cells by regulating the mTORC1/SREBP1/SCD1 pathway.

Formononetin triggers ferroptosis in triple-negative breast cancer cells by regulating the mTORC1/SREBP1/SCD1 pathway.

Journal: Frontiers in pharmacology

Published: May 30, 2024

Integration of scHi-C and scRNA-seq data defines distinct 3D-regulated and biological-context dependent cell subpopulations.

Integration of scHi-C and scRNA-seq data defines distinct 3D-regulated and biological-context dependent cell subpopulations.

Journal: bioRxiv : the preprint server for biology

Published: October 24, 2023

Isolated axillary tumor deposit consistent with primary breast carcinoma: A case report.

Isolated axillary tumor deposit consistent with primary breast carcinoma: A case report.

Journal: World journal of clinical cases

Published: September 11, 2023

TIGIT-Fc as a Potential Therapeutic Agent for Fetomaternal Tolerance.

TIGIT-Fc as a Potential Therapeutic Agent for Fetomaternal Tolerance.

Journal: Frontiers in immunology

Published: January 04, 2021

Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1.

Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1.

Journal: American journal of cancer research

Published: December 18, 2020

Formononetin ameliorates the drug resistance of Taxol resistant triple negative breast cancer by inhibiting autophagy.

Formononetin ameliorates the drug resistance of Taxol resistant triple negative breast cancer by inhibiting autophagy.

Journal: American journal of translational research

Published: September 11, 2020

A New Antifungal Agent (4-phenyl-1, 3-thiazol-2-yl) Hydrazine Induces Oxidative Damage in Candida albicans.

A New Antifungal Agent (4-phenyl-1, 3-thiazol-2-yl) Hydrazine Induces Oxidative Damage in Candida albicans.

Journal: Frontiers in cellular and infection microbiology

Published: July 03, 2020

β-Blocker use is not associated with improved clinical outcomes in women with breast cancer: a meta-analysis.

β-Blocker use is not associated with improved clinical outcomes in women with breast cancer: a meta-analysis.

Journal: Bioscience reports

Published: March 13, 2020

Treatment of murine lupus with TIGIT-Ig.

Treatment of murine lupus with TIGIT-Ig.

Journal: Clinical immunology (Orlando, Fla.)

Published: February 01, 2019

Formononetin Enhances the Tumoricidal Effect of Everolimus in Breast Cancer MDA-MB-468 Cells by Suppressing the mTOR Pathway.

Formononetin Enhances the Tumoricidal Effect of Everolimus in Breast Cancer MDA-MB-468 Cells by Suppressing the mTOR Pathway.

Journal: Evidence-based complementary and alternative medicine : eCAM

Published: December 18, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026